Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.4.1739

Differential microRNA Expression by Solexa Sequencing in the Sera of Ovarian Cancer Patients  

Ji, Ting (Institute of Bioengineering, Zhejiang Sci-Tech University)
Zheng, Zhi-Guo (Zhejiang Cancer Research Institute, Zhejiang Cancer Hospital)
Wang, Feng-Mei (Women's Hospital, School of Medcine, Zhejiang University)
Xu, Li-Jian (Institute of Bioengineering, Zhejiang Sci-Tech University)
Li, Lu-Feng (Institute of Bioengineering, Zhejiang Sci-Tech University)
Cheng, Qi-Hui (Department of Gynaecology and Obstetrics, Hangzhou First People's Hospital)
Guo, Jiang-Feng (Institute of Bioengineering, Zhejiang Sci-Tech University)
Ding, Xian-Feng (Institute of Bioengineering, Zhejiang Sci-Tech University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.4, 2014 , pp. 1739-1743 More about this Journal
Abstract
MicroRNAs are a class of small noncoding RNA which play important regulatory roles in a variety of cancers. MiRNA-specific expression profiles have been reported for several pathological conditions. In this study, we combined large scale parallel Solexa sequencing to identify 11 up-regulated miRNAs and 19 down-regulated miRNAs with computational techniques in the sera of ovarian cancer patients while using healthy serum as the control. Among the above, four miRNAs (miR-22, miR-93, miR-106b, miR-451) were validated by quantitative RT-PCR and found to be significantly aberrantly expressed in the serum of ovarian cancer patients (P<0.05). There were no significant differences between samples from cancer stage I/II and III/IV. However, the levels of miR-106b (p=0.003) and miR-451 (p=0.007) were significantly different in those patients under and over 51 yearsof age. MiR-451 and miR-93 were also specific when analyzed with reference to different levels of CA125. This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis.
Keywords
Ovarian cancer; serum; microRNAs; Solexa sequencing; diagnostic biomarkers;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Creighton C, Reid J, Gunaratne P (2009). Expression profiling of microRNAs by deep sequencing. Brief Bioinform, 10, 490-7.   DOI
2 Chen Y, Zhang L, Hao Q (2013). Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation. Cancer Cell Int, 13, 2867-86.
3 Corney D, Nikitin A (2008). MicroRNA and ovarian cancer. Histol and Histopathol, 23, 1161-9.
4 Cortez M, Calin G (2009). MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther, 9, 703-11.   DOI
5 Dahiya N, Sherman-Baust C, Wang T, et al (2008). MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 18, e2436.
6 Fu X, Tian J, Zhang L, et al (2012). Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett, 9, 1279-86.
7 Garmire L, Subramaniam S (2012). Evaluation of normalization methods in mammalian microRNA-Seq data, RNA, 18, 1279-88.   DOI
8 Liu X, Liu L, Xu Q (2012). MicroRNA as a novel drug target for cancer therapy. Expert Opin Biol Th, 12, 573-80.   DOI   ScienceOn
9 Mitchell P, Parkin R, Kroh E, et al (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 105, 10513-8.   DOI   ScienceOn
10 Moxon S, Jing R, Szittya G, et al (2008). Deep sequencing of tomato short RNAs identifies microRNAs targeting genes involved in fruit ripening. Genome Res, 18, 1602-9.   DOI   ScienceOn
11 Nam E, Yoon H, Kim S, et al (2008), MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res, 14, 2690-5.   DOI   ScienceOn
12 Rathjen T, Pais H, Sweetman D, et al (2009). High throughput sequencing of microRNAs in chicken somites. FEBS Lett, 583, 1422-6.   DOI   ScienceOn
13 Resnick K, Alder H, Hagan J, et al (2009). The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol, 112, 55-9.   DOI   ScienceOn
14 Kurman R, Visvanathan K, Roden R, et al (2008). Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol, 198, 351-6.   DOI   ScienceOn
15 Iorio M, Croce C (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med, 4, 143-59.   DOI
16 Iorio M, Croce C (2012). microRNA involvement in human cancer. Carcinogenesis, 33, 1126-33.   DOI
17 Iorio M, Visone R, Di Leva G, Donati V, et al (2007). MicroRNA signatures in human ovarian cancer. Cancer Res, 67, 8699-707.   DOI   ScienceOn
18 Bartel D (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.   DOI   ScienceOn
19 Brase J, Wuttig D, Kuner R, et al (2010), Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer, 9, 306-15.   DOI   ScienceOn
20 Calin G, Croce C (2006). MicroRNA signatures in human cancers.Nat Rev Cancer 6, 857-66.   DOI   ScienceOn
21 Smith, R. Brooks C, et al (2013). Cancer screening in the United States. CA Cancer J Clin, 2, 87-105.
22 Xu YZ, Xi QH, Ge WL, Zhang XQ (2013). Identification of serum microrna-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac J Cancer Prev, 14, 1057-60.   DOI   ScienceOn
23 Ries L, Reichman M, Lewis D, et al (2003). Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist, 8, 541-52.   DOI   ScienceOn
24 Van M, Helleman J, Berns E, et al (2010). MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell B, 42, 1282-90.   DOI   ScienceOn
25 Rossing M, . Wicklund K, Cushing-Haugen K, et al (2010). Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst, 102, 222-229.   DOI   ScienceOn
26 Sankaranarayanan R, Ferlay J (2006). Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Cl OB, 20, 207-25.
27 Siegel R, Naishadham D, Jemal A (2013). Cancer statistics. CA Cancer J Clin, 63, 11-30.   DOI   ScienceOn
28 Visintin I, Feng Z, Longton G, et al (2008). Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res, 14, 1065-72.   DOI   ScienceOn
29 Visone R, Croce C (2008). MicroRNA. Wiley Encyclopedia of Chemical Biology, 5, 1-9.
30 Wan, SM, Lv F, et al (2012). Identification of genes and microRNAs involved in ovarian carcinogenesis. Asian Pac J Cancer P, 13, 3997-4000.   DOI   ScienceOn
31 Wu Q, Lu Z, Li H, et al (2011). Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnology. 2011, 597145-52.
32 Wyman S, Parkin R, Mitchell P, et al (2009). Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One, 4, e5311.   DOI   ScienceOn
33 Lee R, Ambros V (2001). An extensive class of small RNAs in Caenorhabditis elegans. Science, 294, 862-864.   DOI   ScienceOn
34 Li J, Liang S, Lu X (2010). Potential role of ezrin and its related microRNA in ovarian cancer invasion and metastasis. Zhonghua Fu Chan Ke Za Zhi, 45, 787-92.
35 Livak K, Schmittgen T (2001), Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta] CT method. Methods 25, 402-8.   DOI   ScienceOn
36 Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006.   DOI   ScienceOn